RxDoctor Payments Data

Jenna Franz

Family · Warner Robins, GANPI 1164066106

Payments from drug & device makers

$3,177in general payments, 2019–2025

Across 165 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$508
  • Pfizer$257
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$233
  • AbbVie$210
  • Noven Therapeutics, LLC$209
  • Otsuka America Pharmaceutical, Inc.$196
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$3,11898%
  • Gifts$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,177 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$80,126
Medicare patients
426
Services billed
2,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate41$43,466
EliquisApixaban17$20,488
OzempicSemaglutide11$17,989
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,516
VascepaIcosapent Ethyl14$9,527
Methylprednisolone344$2,131
Fluticasone Propionate76$1,861
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav229$1,545
Albuterol Sulfate HfaAlbuterol Sulfate66$1,366
Gabapentin82$1,272
Azelastine Hcl68$1,236
Omeprazole91$1,208
Levothyroxine Sodium88$1,123
Levocetirizine Dihydrochloride128$1,068
Atorvastatin Calcium118$1,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$37$43,46641 claims
PfizerEliquis$257$20,48817 claims
Novo NordiskOzempic$508$17,98911 claims
GSKTrelegy Ellipta$63$11,51612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →